A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAF(V600E) mutated metastatic non-small cell lung cancer: Results from the OCEAN II study

Lung Cancer

Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM)

Nat Commun

Shen B, Wang C, Zhang L, Zhu Y, Zhang X, Wang X, Guo Z, Wang L, Wang X, Zhu L, Zhou Y, Liao D, Shi M

doi: 10.1038/s41467-026-68554-6

Lung Cancer

Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study

Lancet Respir Med

Lu S, Vynnychenko O, Kulyaba Y, Kuchava V, Ibrahim A, Moiseenko F, Arslan C, Nguyen DT, Petrovic M, Cicin I, Bibichadze K, Cil T, Shi J, Olmez OF, Gogishvili M, Artac M, Nguyen HG, Cornfeld M, Tian C, Munteanu MC, Sette CVM, Bondarenko I, POD1UM-304 Study Team

doi: 10.1016/S2213-2600(25)00209-7

RECOMMENDED

Lung Cancer

Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study

★ 1 Recommended by Dr. med. Martin Frey, Faculty Member

J Clin Med

Veccia A, D'Argento E, Morgillo F, Pizzutilo EG, Vitiello F, Pavan A, Lombardo F, Russano M, Morabito A, Gariazzo E, Genova C, Chiari R, Cristofano A, Delconte A, Vattemi E, Dessi A, Galanti D, Busato S, Palazzolo G, Savastano C, Azzarello G, Verderame F, Mazzi C, Bencardino D, Dipasquale M, Scala A, Della Corte CM, Piscazzi D, Gilli M, Bria E, Caffo O, Gori S, Inno A

doi: 10.3390/jcm15031165

Lung Cancer

The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study

Lung Cancer

Rolfo C, Gerber DE, Kotecha R, Ward JP, Akerley W, Weiss L, Naveh A, Shapira N, Leal T, Langer CJ, LUNAR study investigators

doi: 10.1016/j.lungcan.2025.108802

Lung Cancer

Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial

Clin Lung Cancer

Yang JC, Chen YM, Batra U, Do KH, Sitthideatphaiboon P, Danchaivijitr P, Lee KY, Chindaprasirt J, Yang CT, Chang GC, Charoentum C, Ungtrakul T, Moran JIH, Hartmaier R, Igwegbe I, Gont A, Haskins M, Xu W, Riess JW

doi: 10.1016/j.cllc.2025.10.018

Lung Cancer

A Phase II Study of Accelerated Hyperfractionated Thoracic Radiotherapy With Dose Escalation to 54 Gy With Concurrent Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Long-Term Results at a Single Institution

Clin Lung Cancer

Matsuura K, Komaki R, Kono M, Kudo T, Ono A, Kameoka T, Shintani I, Kusaba H, Kawakubo A, Ando Y, Nishihara K, Iwamoto Y, Shoda H, Katsuta T, Kagemoto M

doi: 10.1016/j.cllc.2025.09.003

Lung Cancer

First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial

Lancet Respir Med

Wang L, Hao X, Hao Y, Hu Y, Chen C, Chen B, Huang Y, Zang A, Wang Y, Chen Z, Zhuang W, Shi J, Ren X, Nie L, Yu G, Luo F, Mao Y, Wang X, Li B, Bai Y, Shi J, Ni H, Yu H, Li J, Wang Q, Zhu J, Shi Y, ASTRUM-002 Study Group

doi: 10.1016/S2213-2600(25)00263-2

RECOMMENDED

Lung Cancer

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

ESMO Open

Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV

doi: 10.1016/j.esmoop.2025.106031

Lung Cancer

PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial

Nat Commun

Zeng L, Ruan Z, Yan H, Qin H, Zeng Z, Zou C, Huang Z, Jiang W, Dai J, Xu S, Song L, Chen Y, Zhang Y, Zeng F, Wei S, Chen S, Liu L, Xiong Y, Wang Z, Deng J, Zhang X, Sun Y, Yang D, Zhou C, Yang H, Li Y, Deng L, Xu Q, Fang C, Chen X, Wang J, Li T, Zhang G, Zhou H, Yang N, Zhang Y

doi: 10.1038/s41467-025-67262-x

Related content

Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM)

Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study

Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study

The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study

Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial

A Phase II Study of Accelerated Hyperfractionated Thoracic Radiotherapy With Dose Escalation to 54 Gy With Concurrent Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Long-Term Results at a Single Institution

First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial